Compare palliative care approaches for people with high-risk AML
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a specialized (targeted) palliative care program versus usual oncology care for people hospitalized with high-risk acute myeloid leukemia (AML). The goal is to see if this palliative approach improves comfort, support, and care planning during intensive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and currently hospitalized with high-risk AML
- Your AML fits at least one high-risk situation (for example, age 60+, prior blood disorder, treatment-related, relapsed, or not responding to treatment)
- You started intensive treatment within the last 5 business days (or a similar intensive hospital treatment), or you started hypomethylating medicine
- You have a caregiver (adult friend or relative) who lives with you or sees you in person at least twice per week
- You cannot have acute promyelocytic leukemia (a specific AML type), and you’re not getting only supportive care
- You must be able to give informed consent and follow study steps; you shouldn’t have been seen by a palliative care clinician in the prior 2 hospital stays in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps older adults with newly diagnosed acute myeloid leukemia (AML) and their caregivers make informed decisions about treatment. You and a caregiver (like a family member or friend) will get extra support to talk through your options.
This study compares starting palliative care early (alongside regular treatment) with receiving standard care only, for people with acute myeloid leukemia. The goal is to see if early palliative support improves quality of life and helps manage symptoms.
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
This trial aims to help doctors choose the best treatment for older adults with acute myeloid leukemia (AML) by using a special health assessment that looks at your overall well-being. The study will compare different treatment options based on this assessment, with the goal of improving outcomes and quality of life.
Hear when a new Relapsed Adult AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.